Tenecteplase
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB00031 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 15 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | posterolateral myocardial infarction | KG + DL |
| 2 | posteroinferior myocardial infarction | KG + DL |
| 3 | septal myocardial infarction | KG + DL |
| 4 | congenital coronary artery anomaly | KG + DL |
| 5 | coronary stenosis | KG + DL |
| 6 | partial deletion of the short arm of chromosome 16 | KG + DL |
| 7 | beta-thalassemia with other manifestations | KG + DL |
| 8 | hemolytic anemia due to glucophosphate isomerase deficiency | KG + DL |
| 9 | pyropoikilocytosis, hereditary | KG + DL |
| 10 | pyruvate kinase deficiency of red cells | KG + DL |
| 11 | heparin cofactor 2 deficiency | KG + DL |
| 12 | antithrombin deficiency type 2 | KG + DL |
| 13 | factor 5 excess with spontaneous thrombosis | KG + DL |
| 14 | thrombophilia | KG + DL |
| 15 | pulmonary embolism (disease) | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.